
## Antonio Procopio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10194152/publications.pdf Version: 2024-02-01



1Circulating miR320b and miR4835.p levels are associated with COVID-19 in-hospital mortality. Mechanisms of Ageing and Development, 2022, 202, 111636.2.2152Circulating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes. Mechanisms of Ageing and Development, 2022, 204, 111667.2.2123The application of cancer stem cell model in malignant mesothelioma. Critical Reviews in Oncology/Hematology. 2022, 174, 103698.2.024Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to to cillzumab in COVID-19 patients. Mechanisms of Ageing and Development, 2021, 193, 111413.2.2895CD31+ Extracellular Vesicles From Patients With Type 2 Diabetes Shuttle a miRNA Signature Associated With Cardiovascular Complications. Diabetes, 2021, 70, 240-254.0.3386Cellular senescence and senescence-associated secretory phenotype (SASP) in aging process., 2021, .2217Circulating Inflamma-miRs as Potential Biomarkers of Cognitive Impairment in Patients Affected by Alzheimerä C ** Disease. Frontiers in Aging Neuroscience, 2021, 13, 647015.1.7228Anti-SASP and anti-inflammatory activity of resveratrol, curcumin and 12-caryophyllene association on mutuple scierosis. Multiple Scierosis and Related Disorders, 2021, 54, 103126.0.91210Prevalence of residual Inflammatory risk and associated clinical variables in patients with type 22.240	IF CITATIONS
2       Mechanisms of Ageing and Development, 2022, 204, 111667.       2.2       12         3       The application of cancer stem cell model in malignant mesothelioma. Critical Reviews in Oncology/Hematology, 2022, 174, 103698.       2.0       2         4       Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients. Mechanisms of Ageing and Development, 2021, 193, 111413.       2.2       89         5       CD31+ Extracellular Vesicles From Patients With Type 2 Diabetes Shuttle a miRNA Signature Associated With Cardiovascular Complications. Diabetes, 2021, 70, 240-254.       0.3       38         6       Cellular senescence and senescence-associated secretory phenotype (SASP) in aging process., 2021, , 75-88.       2         7       Circulating Inflamma-miRs as Potential Biomarkers of Cognitive Impairment in Patients Affected by Alzheimera€ Ms Disease. Frontiers in Aging Neuroscience, 2021, 13, 647015.       1.7       22         8       Anti-SASP and anti-inflammatory activity of resveratrol, curcumin and β-caryophyllene association on human endothelial and monocytic cells. Biogerontology, 2021, 22, 297-313.       2.0       21         9       Potential prognostic value of circulating inflamma-miR-146a-5p and miR-125a-5p in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 54, 103126.       0.9       12	ortality. 2.2 15
3       Oncology/Hematology, 2022, 174, 103698.       20       21         4       Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to to cocilizumab in COVID-19 patients. Mechanisms of Ageing and Development, 2021, 193, 111413.       2.2       89         5       CD31+ Extracellular Vesicles From Patients With Type 2 Diabetes Shuttle a miRNA Signature Associated With Cardiovascular Complications. Diabetes, 2021, 70, 240-254.       0.3       38         6       Cellular senescence and senescence-associated secretory phenotype (SASP) in aging process., 2021, , 75-88.       2         7       Circulating Inflamma-miRs as Potential Biomarkers of Cognitive Impairment in Patients Affected by Alzheimeräe <sup>TMS</sup> Disease. Frontiers in Aging Neuroscience, 2021, 13, 647015.       1.7       22         8       Anti-SASP and anti-inflammatory activity of resveratrol, curcumin and <sup>12</sup> -caryophyllene association on human endothelial and monocytic cells. Biogerontology, 2021, 22, 297-313.       2.0       21         9       Potential prognostic value of circulating inflamma-miR-146a-5p and miR-125a-5p in relapsing-remitting multiple sclerosis and Related Disorders, 2021, 54, 103126.       0.9       12         10       Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2       2.0       21	comes. 2.2 12
4       to tocilizumab in COVID-19 patients. Mechanisms of Ageing and Development, 2021, 193, 111413.       2.2       89         5       CD31+ Extracellular Vesicles From Patients With Type 2 Diabetes Shuttle a miRNA Signature Associated       0.3       38         6       Cellular senescence and senescence-associated secretory phenotype (SASP) in aging process. , 2021, , 75-88.       2         7       Circulating Inflamma-miRs as Potential Biomarkers of Cognitive Impairment in Patients Affected by Alzheimerãe™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 647015.       1.7       22         8       Anti-SASP and anti-inflammatory activity of resveratrol, curcumin and î²-caryophyllene association on human endothelial and monocytic cells. Biogerontology, 2021, 22, 297-313.       2.0       21         9       Potential prognostic value of circulating inflamma-miR-146a-5p and miR-125a-5p in relapsing-remitting 0.9       12         10       Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2       2.0       21	ח 2.0 2
b       With Cardiovascular Complications. Diabetes, 2021, 70, 240-254.       0.3       38         6       Cellular senescence and senescence-associated secretory phenotype (SASP) in aging process., 2021, ,       2         7       Circulating Inflamma-miRs as Potential Biomarkers of Cognitive Impairment in Patients Affected by       1.7       22         8       Anti-SASP and anti-inflammatory activity of resveratrol, curcumin and β-caryophyllene association on human endothelial and monocytic cells. Biogerontology, 2021, 22, 297-313.       2.0       21         9       Potential prognostic value of circulating inflamma-miR-146a-5p and miR-125a-5p in relapsing-remitting       0.9       12         10       Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2       0.8       40	al non-response 2.2 89 93, 111413.
6       75-88.       2         7       Circulating Inflamma-miRs as Potential Biomarkers of Cognitive Impairment in Patients Affected by Alzheimer〙s Disease. Frontiers in Aging Neuroscience, 2021, 13, 647015.       1.7       22         8       Anti-SASP and anti-inflammatory activity of resveratrol, curcumin and β-caryophyllene association on human endothelial and monocytic cells. Biogerontology, 2021, 22, 297-313.       2.0       21         9       Potential prognostic value of circulating inflamma-miR-146a-5p and miR-125a-5p in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 54, 103126.       0.9       12         10       Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2       8.8       40	ature Associated 0.3 38
<ul> <li>Alzheimer〙s Disease. Frontiers in Aging Neuroscience, 2021, 13, 647015.</li> <li>Anti-SASP and anti-inflammatory activity of resveratrol, curcumin and β-caryophyllene association on human endothelial and monocytic cells. Biogerontology, 2021, 22, 297-313.</li> <li>Potential prognostic value of circulating inflamma-miR-146a-5p and miR-125a-5p in relapsing-remitting 0.9 12</li> <li>Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2</li> <li>Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2</li> </ul>	ocess., 2021,, 2
<ul> <li><sup>8</sup> human endothelial and monocytic cells. Biogerontology, 2021, 22, 297-313.</li> <li><sup>9</sup> Potential prognostic value of circulating inflamma-miR-146a-5p and miR-125a-5p in relapsing-remitting 0.9 12</li> <li><sup>10</sup> Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2</li> </ul>	Affected by 1.7 22
<ul> <li><sup>9</sup> multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 54, 103126.</li> <li>O.9 12</li> <li>O.9 12</li> <li>Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2</li> </ul>	ssociation on 2.0 21
	psing-remitting 0.9 12
	n type 2 2.2 40
Small extracellular vesicles deliver miRâ€21 and miRâ€217 as proâ€senescence effectors to endothelial cells. Journal of Extracellular Vesicles, 2020, 9, 1725285.	s to endothelial cells. 5.5 104
Pleiotropic effects of polyphenols on glucose and lipid metabolism: Focus on clinical trials. Ageing 5.0 30 Research Reviews, 2020, 61, 101074.	ls. Ageing 5.0 30
<ul> <li>SARS-CoV-2 identification in lungs, heart and kidney specimens by transmission and scanning electron</li> <li>microscopy. European Review for Medical and Pharmacological Sciences, 2020, 24, 5186-5188.</li> </ul>	
Raccomandazioni per la gestione di variabili preanalitiche legate al paziente nella determinazione del 14 PSA in fase di screening e follow-up di cancro prostatico. Rivista Italiana Della Medicina Di 0.2 0 Laboratorio, 2020, 16, .	ninazione del Di 0.2 0
The Experimental Pathology at Ancona: 50ÂYears of Exciting and Pioneering Research on Human Pathology. , 2020, , 43-55.	n Human o
A Practical Guide to miRNA Target Prediction. Methods in Molecular Biology, 2019, 1970, 1-13. 0.4 18	0, 1-13. 0.4 18
Where Metabolism Meets Senescence: Focus on Endothelial Cells. Frontiers in Physiology, 2019, 10, 17 1523. 1.3 103	gy, 2019, 10, 1.3 103

18 MitomiRs in Human Inflamm-aging. , 2019, , 1681-1708.

#	Article	IF	CITATIONS
19	Modulation of soluble receptor for advanced glycation end-products (RAGE) isoforms and their ligands in healthy aging. Aging, 2019, 11, 1648-1663.	1.4	32
20	Diagnostic performance of new and classic CSF biomarkers in age-related dementias. Aging, 2019, 11, 2420-2429.	1.4	20
21	MiR-146a-5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor-alpha inhibitor adalimumab. British Journal of Dermatology, 2018, 179, 787-789.	1.4	19
22	Short-term sustained hyperglycaemia fosters an archetypal senescence-associated secretory phenotype in endothelial cells and macrophages. Redox Biology, 2018, 15, 170-181.	3.9	102
23	Anti-senescence compounds: A potential nutraceutical approach to healthy aging. Ageing Research Reviews, 2018, 46, 14-31.	5.0	130
24	IL-7-induced phosphorylation of the adaptor Crk-like and other targets. Cellular Signalling, 2018, 47, 131-141.	1.7	6
25	Inflammageing and metaflammation: The yin and yang of type 2 diabetes. Ageing Research Reviews, 2018, 41, 1-17.	5.0	182
26	Differential microRNA expression between decidual and peripheral blood natural killer cells in early pregnancy. Human Reproduction, 2018, 33, 2184-2195.	0.4	18
27	The mitomiR/Bcl-2 axis affects mitochondrial function and autophagic vacuole formation in senescent endothelial cells. Aging, 2018, 10, 2855-2873.	1.4	34
28	Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing. Ageing Research Reviews, 2018, 48, 87-98.	5.0	80
29	MitomiRs in Human Inflamm-Aging. , 2018, , 1-29.		2
30	From Oxidative Stress Damage to Pathways, Networks, and Autophagy via MicroRNAs. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-16.	1.9	68
31	Age-related M1/M2 phenotype changes in circulating monocytes from healthy/unhealthy individuals. Aging, 2018, 10, 1268-1280.	1.4	48
32	Exosome-based immunomodulation during aging: A nano-perspective on inflamm-aging. Mechanisms of Ageing and Development, 2017, 168, 44-53.	2.2	76
33	ldentification of miR-31-5p, miR-141-3p, miR-200c-3p, and GLT1 as human liver aging markers sensitive to donor-recipient age-mismatch in transplants. Aging Cell, 2017, 16, 262-272.	3.0	48
34	Epigenetic effects of physical activity in elderly patients with cardiovascular disease. Experimental Gerontology, 2017, 100, 17-27.	1.2	17
35	Mitochondrial (Dys) Function in Inflammaging: Do MitomiRs Influence the Energetic, Oxidative, and Inflammatory Status of Senescent Cells?. Mediators of Inflammation, 2017, 2017, 1-11.	1.4	48
36	Expression Levels and Clinical Significance of miR-21-5p, miR-let-7a, and miR-34c-5p in Laryngeal Squamous Cell Carcinoma. BioMed Research International, 2017, 2017, 1-9.	0.9	31

#	Article	IF	CITATIONS
37	Progress of research on microRNAs with diagnostic value in asbestos exposure: A call for method standardization. BioScience Trends, 2017, 11, 105-109.	1.1	6
38	The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. Oncotarget, 2017, 8, 58642-58653.	0.8	58
39	Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM. Oncotarget, 2017, 8, 93338-93348.	0.8	21
40	Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis. Oncotarget, 2016, 7, 58606-58637.	0.8	69
41	"Inflammaging―as a Druggable Target: A Senescence-Associated Secretory Phenotype—Centered View of Type 2 Diabetes. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-10.	1.9	93
42	Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?. Diabetes, Obesity and Metabolism, 2016, 18, 855-867.	2.2	57
43	Bioinformatic tools for microRNA dissection. Nucleic Acids Research, 2016, 44, 24-44.	6.5	182
44	Physical activity and progenitor cell-mediated endothelial repair in chronic heart failure: Is there a role for epigenetics?. Mechanisms of Ageing and Development, 2016, 159, 71-80.	2.2	22
45	Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells. Oncotarget, 2016, 7, 11945-11958.	0.8	69
46	Endothelial Cell Senescence and Inflammaging: MicroRNAs as Biomarkers and Innovative Therapeutic Tools. Current Drug Targets, 2016, 17, 388-397.	1.0	23
47	Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes. Clinical Epigenetics, 2015, 7, 56.	1.8	83
48	Micro <scp>RNA</scp> â€34câ€5p is related to recurrence in laryngeal squamous cell carcinoma. Laryngoscope, 2015, 125, E306-12.	1.1	26
49	MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications. Oncotarget, 2015, 6, 35372-35382.	0.8	107
50	DNA damage response (DDR) and senescence: shuttled inflamma-miRNAs on the stage of inflamm-aging. Oncotarget, 2015, 6, 35509-35521.	0.8	127
51	Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells. Aging, 2014, 6, 771-786.	1.4	105
52	Hormone replacement therapy enhances IGF-1 signaling in skeletal muscle by diminishing miR-182 and miR-223 expressions: a study on postmenopausal monozygotic twin pairs. Aging Cell, 2014, 13, 850-861.	3.0	47
53	Use of dietary phytochemicals to target inflammation, fibrosis, proliferation, and angiogenesis in uterine tissues: Promising options for prevention and treatment of uterine fibroids?. Molecular Nutrition and Food Research, 2014, 58, 1667-1684.	1.5	45
54	Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy – A study with monozygotic twin pairs. Mechanisms of Ageing and Development, 2014, 143-144, 1-8.	2.2	45

#	Article	IF	CITATIONS
55	Effect of aging on microRNAs and regulation of pathogen recognition receptors. Current Opinion in Immunology, 2014, 29, 29-37.	2.4	34
56	Admission levels of circulating miR-499-5p and risk of death in elderly patients after acute non-ST elevation myocardial infarction. International Journal of Cardiology, 2014, 172, e276-e278.	0.8	46
5 <b>7</b>	MitomiRs in human inflamm-aging: A hypothesis involving miR-181a, miR-34a and miR-146a. Experimental Gerontology, 2014, 56, 154-163.	1.2	179
58	Toll like receptor signaling in "inflammaging― microRNA as new players. Immunity and Ageing, 2013, 10, 11.	1.8	114
59	The p53 codon 72 (Arg72Pro) polymorphism is associated with the degree of insulin resistance in type 2 diabetic subjects: a cross-sectional study. Acta Diabetologica, 2013, 50, 429-436.	1.2	28
60	Stemness of T cells and the hematopoietic stem cells: Fate, memory, niche, cytokines. Cytokine and Growth Factor Reviews, 2013, 24, 485-501.	3.2	8
61	Circulating microRNAs (miRs) for diagnosing acute myocardial infarction: An exciting challenge. International Journal of Cardiology, 2013, 167, 3028-3029.	0.8	18
62	Telomere/telomerase system impairment in circulating angiogenic cells of geriatric patients with heart failure. International Journal of Cardiology, 2013, 164, 99-105.	0.8	17
63	Conventional and novel diagnostic biomarkers of acute myocardial infarction: a promising role for circulating microRNAs. Biomarkers, 2013, 18, 547-558.	0.9	31
64	Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. International Journal of Cardiology, 2013, 167, 531-536.	0.8	214
65	MiR-146a as marker of senescence-associated pro-inflammatory status in cells involved in vascular remodelling. Age, 2013, 35, 1157-1172.	3.0	172
66	HtrA1 in human urothelial bladder cancer: A secreted protein and a potential novel biomarker. International Journal of Cancer, 2013, 133, n/a-n/a.	2.3	29
67	MicroRNAs linking inflamm-aging, cellular senescence and cancer. Ageing Research Reviews, 2013, 12, 1056-1068.	5.0	173
68	Anti-inflammatory effect of ubiquinol-10 on young and senescent endothelial cells via miR-146a modulation. Free Radical Biology and Medicine, 2013, 63, 410-420.	1.3	65
69	Putative miRNAs for the diagnosis of dyslexia, dyspraxia, and specific language impairment. Epigenetics, 2013, 8, 1023-1029.	1.3	6
70	Low FasL levels promote proliferation of human bone marrow-derived mesenchymal stem cells, higher levels inhibit their differentiation into adipocytes. Cell Death and Disease, 2013, 4, e594-e594.	2.7	23
71	Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment. Current Pharmaceutical Design, 2013, 19, 1710-1719.	0.9	26
72	Circulating inflamma-miRs in aging and age-related diseases. Frontiers in Genetics, 2013, 4, 121.	1.1	154

#	Article	IF	CITATIONS
73	Genes of Human Longevity: An Endless Quest?. Current Vascular Pharmacology, 2013, 12, 707-717.	0.8	22
74	Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment. Current Pharmaceutical Design, 2013, 19, 1710-1719.	0.9	17
75	Cellular senescence in cardiovascular diseases: potential age-related mechanisms and implications for treatment. Current Pharmaceutical Design, 2013, 19, 1710-9.	0.9	36
76	Telomere/Telomerase System: A New Target of Statins Pleiotropic Effect?. Current Vascular Pharmacology, 2012, 10, 216-224.	0.8	45
77	How many patients need statin treatment in a low-cardiovascular-risk country? Low-density lipoprotein-cholesterol target and distance from target distribution in an Italian cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 327-336.	1.1	13
78	Age-related differences in the expression of circulating microRNAs: miR-21 as a new circulating marker of inflammaging. Mechanisms of Ageing and Development, 2012, 133, 675-685.	2.2	218
79	Aged-related increase of high sensitive Troponin T and its implication in acute myocardial infarction diagnosis of elderly patients. Mechanisms of Ageing and Development, 2012, 133, 300-305.	2.2	64
80	Dystrophin Is Required for the Normal Function of the Cardio-Protective KATP Channel in Cardiomyocytes. PLoS ONE, 2011, 6, e27034.	1.1	18
81	Leukocyte telomere length is associated with complications of Type 2 diabetes mellitus. Diabetic Medicine, 2011, 28, 1388-1394.	1.2	89
82	Predicting microRNA modulation in human prostate cancer using a simple String IDentifier (SID1.0). Journal of Biomedical Informatics, 2011, 44, 615-620.	2.5	20
83	Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks. Current Pharmaceutical Design, 2010, 16, 725-733.	0.9	32
84	Dexamethasone Affects FAS-and Serum Deprivation-Induced Cell Death of Human Osteoblastic Cells through Survivin Regulation. International Journal of Immunopathology and Pharmacology, 2010, 23, 1153-1165.	1.0	11
85	The Plexin-A1 Receptor Activates Vascular Endothelial Growth Factor-Receptor 2 and Nuclear Factor-κB to Mediate Survival and Anchorage-Independent Growth of Malignant Mesothelioma Cells. Cancer Research, 2009, 69, 1485-1493.	0.4	40
86	The Effects of Insulin and Insulin-Like Growth Factors on Tumor Vascularization: New Insights of Insulin-Like Growth Factor Family in Cancer. Current Medicinal Chemistry, 2009, 16, 3931-3942.	1.2	6
87	Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. Lung Cancer, 2009, 66, 184-190.	0.9	31
88	Leukocyte telomere shortening in elderly Type2DM patients with previous myocardial infarction. Atherosclerosis, 2009, 206, 588-593.	0.4	81
89	Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis. Clinical and Experimental Immunology, 2008, 80, 360-365.	1.1	20
90	Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. Clinical and Experimental Immunology, 2008, 81, 368-372.	1.1	67

#	Article	IF	CITATIONS
91	GABAergic miniature spontaneous activity is increased in the CA1 hippocampal region of dystrophic mdx mice. Neuromuscular Disorders, 2008, 18, 220-226.	0.3	27
92	C-reactive protein is directly related to plasminogen activator inhibitor type 1 (PAI-1) levels in diabetic subjects with the 4G allele at position â^675 of the PAI-1 gene. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 220-226.	1.1	9
93	Enhanced Antitumor Therapy by Inhibition of p21waf1 in Human Malignant Mesothelioma. Clinical Cancer Research, 2008, 14, 5099-5107.	3.2	35
94	Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies. Current Medicinal Chemistry, 2008, 15, 631-641.	1.2	22
95	Molecular Targets and Targeted Therapies for Malignant Mesothelioma. Current Medicinal Chemistry, 2008, 15, 855-867.	1.2	33
96	Semaphorin3A signaling controls Fas (CD95)-mediated apoptosis by promoting Fas translocation into lipid rafts. Blood, 2008, 111, 2290-2299.	0.6	89
97	α-Tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: Implication for sensitisation of resistant cancer cells to TRAIL apoptosis. FEBS Letters, 2006, 580, 1925-1931.	1.3	52
98	Human neoplastic mesothelial cells express voltage-gated sodium channels involved in cell motility. International Journal of Biochemistry and Cell Biology, 2006, 38, 1146-1159.	1.2	51
99	Interleukin-6 is a determinant of PAI-1 levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene. Thrombosis and Haemostasis, 2006, 95, 587-588.	1.8	1
100	Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function. Blood, 2006, 107, 3321-3329.	0.6	146
101	Emerging Role of Stromal Fibroblasts in Epithelial Cancer. Current Signal Transduction Therapy, 2006, 1, 273-283.	0.3	0
102	Targeting 5-Lipoxygenase Signaling Pathways to Reverse Drug Resistance in Cancer. Letters in Drug Design and Discovery, 2006, 3, 459-461.	0.4	0
103	Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis. BMC Cancer, 2006, 6, 130.	1.1	25
104	Neuronal Semaphorins Regulate a Primary Immune Response. Current Neurovascular Research, 2006, 3, 295-305.	0.4	20
105	5-Lipoxygenase regulates senescence-like growth arrest by promoting ROS-dependent p53 activation. EMBO Journal, 2005, 24, 170-179.	3.5	106
106	α-Tocopheryl Succinate Inhibits Malignant Mesothelioma byDisrupting the Fibroblast Growth Factor Autocrine Loop. Journal of Biological Chemistry, 2005, 280, 25369-25376.	1.6	109
107	Induction of Stem Cell Factor/c-Kit/Slug Signal Transduction in Multidrug-resistant Malignant Mesothelioma Cells. Journal of Biological Chemistry, 2004, 279, 46706-46714.	1.6	84
108	5â€Lipoxygenase antagonizes genotoxic stressâ€induced apoptosis by altering p53 nuclear trafficking. FASEB Journal, 2004, 18, 1740-1742.	0.2	40

ΑΝΤΟΝΙΟ ΡΓΟΟΡΙΟ

#	Article	IF	CITATIONS
109	Crossâ€talk between vascular endothelial growth factor and semaphorinâ€3A pathway in the regulation of normal and malignant mesothelial cell proliferation. FASEB Journal, 2004, 18, 1-20.	0.2	68
110	α-Tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells. British Journal of Cancer, 2004, 90, 1644-1653.	2.9	59
111	FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene, 2004, 23, 7753-7760.	2.6	87
112	Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. International Journal of Cancer, 2004, 109, 322-328.	2.3	43
113	A vitamin E analogue suppresses malignant mesothelioma in a preclinical model: A future drug against a fatal neoplastic disease?. International Journal of Cancer, 2004, 109, 641-642.	2.3	55
114	Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic treatments. Critical Reviews in Oncology/Hematology, 2004, 50, 101-109.	2.0	16
115	α-Tocopheryl succinate inhibits proliferation of mesothelioma cells by selective down-regulation of fibroblast growth factor receptors. Biochemical and Biophysical Research Communications, 2004, 318, 636-641.	1.0	20
116	Familial Mediterranean fever is no longer a rare disease in Italy. European Journal of Human Genetics, 2003, 11, 50-56.	1.4	115
117	Retinoic acid inhibits fibronectin and laminin synthesis and cell migration of human pleural mesothelioma in vitro. Oncology Reports, 2002, 9, 205.	1.2	3
118	Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. Journal of Pathology, 2002, 197, 218-223.	2.1	29
119	Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen. Oncogene, 2002, 21, 2896-2900.	2.6	62
120	Methionine Aminopeptidase-2 Regulates Human Mesothelioma Cell Survival. American Journal of Pathology, 2001, 159, 721-731.	1.9	74
121	Nutrients and Gene Expression. , 2001, 89, 23-52.		5
122	Platelet Activation and Platelet-erythrocyte Aggregates in End-stage Renal Disease Patients on Hemodialysis. Thrombosis and Haemostasis, 2001, 86, 834-839.	1.8	39
123	Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. Journal of Pathology, 2001, 193, 468-475.	2.1	326
124	Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes and Cancer, 2001, 30, 111-111.	1.5	2
125	Association of SV40 with human tumours. Seminars in Cancer Biology, 2001, 11, 49-61.	4.3	99
126	SV40 replication in human mesothelial cells induces HGF/Met receptor activation: A model for viral-related carcinogenesis of human malignant mesothelioma. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 12032-12037.	3.3	135

#	Article	IF	CITATIONS
127	Basic fibroblast growth factor in mesothelioma pleural effusions: Correlation with patient survival and angiogenesis. International Journal of Oncology, 2001, 18, 1093-8.	1.4	23
128	5â€Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB Journal, 2001, 15, 2326-2336.	0.2	118
129	Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro. Journal of Cellular Physiology, 2000, 185, 126-134.	2.0	18
130	Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes and Cancer, 2000, 29, 173-179.	1.5	56
131	Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells International Journal of Molecular Medicine, 2000, 5, 591-6.	1.8	28
132	Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma. Human Pathology, 2000, 31, 1341-1345.	1.1	8
133	Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma. Human Pathology, 2000, 31, 1341-1345.	1.1	7
134	Migration of mesothelioma cells correlates with histotype-specific synthesis of extracellular matrix International Journal of Molecular Medicine, 1999, 4, 67-71.	1.8	14
135	Modulation of integrin expression on mesotheliomas: the role of different histotypes in invasiveness International Journal of Oncology, 1999, 15, 437-42.	1.4	1
136	Cyclooxygenase-independent induction of p21WAF-1/cip1, apoptosis and differentiation by L-745,337, a selective PGH synthase-2 inhibitor, and salicylate in HT-29 cells. Apoptosis: an International Journal on Programmed Cell Death, 1999, 4, 151-162.	2.2	9
137	Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. European Respiratory Journal, 1999, 13, 527-534.	3.1	59
138	Basal Lamina Reduplication in Malignant Epithelioid Pleural Mesothelioma. Ultrastructural Pathology, 1998, 22, 467-475.	0.4	6
139	Increased Levels of Soluble P-Selectin in Hypercholesterolemic Patients. Circulation, 1998, 97, 953-957.	1.6	170
140	Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nature Medicine, 1997, 3, 908-912.	15.2	244
141	Extracellular adenosine $5\hat{a}\in^2$ triphosphate involvement in the death of LAK-engaged human tumor cells via P2X-receptor activation. Immunology Letters, 1997, 55, 69-78.	1.1	21
142	Surfactant Protein A-Producing Cells in Human Fetal Lung Are Good Targets for Recombinant Adenovirus-Mediated Gene Transfer. Pediatric Research, 1996, 40, 142-147.	1.1	1
143	TRANSMEMBRANE ION FLUX MODIFIERS VERAPAMIL AND OUABAIN MODULATE CYTOTOXIC EFFECTS OF EXTRACELLULAR ATP ON HUMAN TUMOR-CELLS IN-VITRO. International Journal of Oncology, 1993, 3, 847-51.	1.4	2
144	Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer-and lymphokine-activated-killer-mediated cytotoxicity. Cancer Immunology, Immunotherapy, 1992, 34, 272-278.	2.0	8

ANTONIO PROCOPIO

#	Article	IF	CITATIONS
145	Adhesion and activation molecules expressed by human natural killer cells. Cytotechnology, 1991, 5, 117-121.	0.7	3
146	Cadmium inhibits spontaneous (NK), antibody-mediated (ADCC) and IL-2-stimulated cytotoxic functions of natural killer cells. Immunopharmacology, 1990, 20, 73-80.	2.0	23
147	Effects of protein kinase C (PK-C) activators and inhibitors on human large granular lymphocytes (LGL): Role of PK-C on natural killer (NK) activity. Cellular Immunology, 1989, 118, 470-481.	1.4	27
148	Effects of cadmium on lymphocyte activation. Biochimica Et Biophysica Acta - Molecular Cell Research, 1989, 1011, 25-32.	1.9	42
149	Cadmium-induced inhibition of human lymphocyte proliferation. International Journal of Immunopharmacology, 1988, 10, 145.	1.1	0
150	Proliferative effects of 12-O-Tetradecanoylphorbol-13-acetate (TPA) and calcium ionophores on human large granular lymphocytes (LGL). Cellular Immunology, 1988, 113, 70-81.	1.4	12
151	Production of multiple cytokines by clones of human large granular lymphocytes. Cancer Immunology, Immunotherapy, 1985, 19, 121-6.	2.0	52
152	Hairy cell leukemia: Absence of natural killer activity and of interleukin 1 release in OKM-1+ spleen hairy cells. Clinical Immunology and Immunopathology, 1983, 26, 47-55.	2.1	16
153	Increased monocyte phagocytosis in cancer patients. European Journal of Cancer, 1980, 16, 1315-1320.	1.0	16